- Home
- CHRS vs SVII Comparison
CHRS vs SVII Comparison
Compare CHRS & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SVII
- Stock Information
- Founded
- CHRS 2010
- SVII 2021
- Country
- CHRS United States
- SVII United States
- Employees
- CHRS N/A
- SVII N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SVII Blank Checks
- Sector
- CHRS Health Care
- SVII Finance
- Exchange
- CHRS Nasdaq
- SVII Nasdaq
- Market Cap
- CHRS 112.5M
- SVII 113.1M
- IPO Year
- CHRS 2014
- SVII 2022
- Fundamental
- Price
- CHRS $0.76
- SVII $11.66
- Analyst Decision
- CHRS Strong Buy
- SVII
- Analyst Count
- CHRS 4
- SVII 0
- Target Price
- CHRS $5.26
- SVII N/A
- AVG Volume (30 Days)
- CHRS 1.7M
- SVII 4.6K
- Earning Date
- CHRS 05-12-2025
- SVII 01-01-0001
- Dividend Yield
- CHRS N/A
- SVII N/A
- EPS Growth
- CHRS N/A
- SVII N/A
- EPS
- CHRS N/A
- SVII 0.21
- Revenue
- CHRS $272,251,000.00
- SVII N/A
- Revenue This Year
- CHRS N/A
- SVII N/A
- Revenue Next Year
- CHRS N/A
- SVII N/A
- P/E Ratio
- CHRS N/A
- SVII $55.99
- Revenue Growth
- CHRS 19.87
- SVII N/A
- 52 Week Low
- CHRS $0.66
- SVII $11.03
- 52 Week High
- CHRS $2.43
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- SVII 70.10
- Support Level
- CHRS $0.71
- SVII $11.63
- Resistance Level
- CHRS $1.06
- SVII $11.69
- Average True Range (ATR)
- CHRS 0.08
- SVII 0.00
- MACD
- CHRS -0.03
- SVII -0.00
- Stochastic Oscillator
- CHRS 12.44
- SVII 75.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.